慢性乙型肝炎临床治疗的现状与挑战  

Current state and challenges of clinical treatment of chronic hepatitis B

作　　者：史继静[1] 常文仙 李元元[3] 王福生[1,3] SHI Jijing CHANG Wenxian LI Yuanyuan WANG Fusheng(Department of Infectious Diseases, 302 Military Hospital of China-Peking University Teaching Hospital, Beijing 100039, China Bengbu Medical College, Bengbu 233000, China Department of Infectious Diseases, Beijing 302 Hospital, Beijing 100039, China)

机构地区：[1]北京大学解放军302医院教学医院感染性疾病诊疗与研究中心,北京100039 [2]蚌埠医学院,蚌埠233000 [3]中国人民解放军第三0二医院感染性疾病诊疗与研究中心,北京100039

出　　处：《科技导报》2016年第20期34-39,共6页Science & Technology Review

摘　　要：病毒本身和机体免疫应答是影响HBV感染病情进展和临床转归的重要因素。目前免疫学研究及临床观察结果表明,单纯的抗病毒治疗无法重建慢性乙型肝炎患者的抗病毒免疫功能,因而无法彻底治愈HBV感染。联合新的免疫治疗策略,根据疾病的不同阶段采取针对性的治疗方案,可能是实现HBV感染治愈的有效方法。本文综述慢性乙型肝炎治疗的现状与进展。HBV itself and the host immune responses determine the outcome of HBV infection, which can be either acute or chronic. Current immunological researches and clinical observations have revealed that existing antiviral drugs cannot restore the antiviral immunity of patients with chronic hepatitis B, and therefore can not completely eliminate HBV. Combined with new immunotherapy, according to the different stages of disease to adopt individualized treatment, may be an effective way to achieve the cure of HBV infection. Here, the current progress and challenges of chronic HBV infection will be reviewed.

关 键 词：慢性乙型肝炎 疾病进展 抗病毒治疗 免疫治疗 

分 类 号：R512.62[医药卫生—内科学]